参芪扶正注射液联合TP方案治疗非小细胞肺癌术后临床观察  

Clinical Observation on Shenqifuzheng Injection Combined with TP Regimen in the Treatment of Non-Small Cell Lung Cancer

作　　者：龚玉爱 舒诚荣[1] 王汉姣 韩琦[1] GONG Yuai;SHU Chengrong;WANG Hanjiao;HAN Qi(Department of Oncology,Xianning Central Hospital,The First Affiliated Hospital of Hubei University of Science and Technology,Xianning,Hubei,China 437100)

机构地区：[1]湖北省咸宁市中心医院·湖北科技学院附属第一医院肿瘤科

出　　处：《中国药业》2019年第22期46-49,共4页China Pharmaceuticals

基　　金：湖北省科技计划项目[2014CFB309]

摘　　要：目的探讨参芪扶正注射液联合TP方案治疗非小细胞肺癌(NSCLC)术后的疗效及对患者免疫功能和肿瘤标志物的影响。方法选取医院2014年1月至2017年1月收治的NSCLC术后患者84例,按随机数字表法分为研究组和对照组,各42例。两组患者均予TP方案(多西他赛^+顺铂)治疗,研究组患者加用参芪扶正注射液。两组均以21 d为1个疗程,共治疗4个疗程。结果研究组患者疾病控制率(DCR)、临床获益率(RR)分别为88.09%和73.81%,显著高于对照组的66.67%和50.00%(P<0.05)。与治疗前比较,两组患者治疗后的血清癌胚抗原(CEA)、细胞角蛋白19可溶性片段(CYFRA21-1)及神经元特异烯醇化酶(NSE)水平均显著降低,且研究组上述指标均显著优于对照组(P<0.05);研究组患者治疗后的CD3^+,CD4^+,CD8^+,CD4^+/CD8^+无显著变化(P>0.05),对照组患者治疗后的CD3^+,CD4^+,CD4^+/CD8^+显著降低(P<0.05)。研究组患者恶心呕吐、白细胞减少的发生率显著低于对照组(P<0.05);研究组与对照组术后复发转移率无显著差异(7.14%比4.76%,χ2=0.213,P=0.645>0.05)。结论参芪扶正注射液可调节NSCLC术后患者机体的免疫功能,减少化疗相关不良反应。Objective To investigate the effect of Shenqifuzheng Injection combined with TP regimen in the treatment of non-small cell lung cancer(NSCLC)and its effect on immune function and tumor markers.Methods Totally 84 patients with NSCLC after operation admitted to our hospital from January 2014 to January 2017 were selected and divided into the study group and the control group according to the random number table method,42 cases in each group.The patients in the two groups were treated with TP regimen(docetaxel and cisplatin),on this basis,the patients in the study group were treated with Shenqifuzheng Injection.Both groups were treated for 4 courses with 21 d as a course.Results The disease control rate(DCR),clinical benefit rate(CBR)of the study group were 88.09%and 73.81%,which were significantly higher than 66.67%and 50.00%of the control group(P<0.05).Compared with those before treatment,the levels of serum carcinoembryonic antigen(CEA),cytokeratin 19 soluble fragment(CYFRA21-1)and neuron-specific enolase(NSE)in the two groups were significantly decreased after treatment,and the above indexes in the study group were significantly better than those in the control group(P<0.05).There was no significant change in CD3+,CD4+,CD8+,CD4+/CD8+in the study group before and after treatment(P>0.05),while the CD3+,CD4+,CD4+/CD8+in the control group were significantly decreased after treatment(P<0.05).The incidence of nausea,vomiting and leukopenia in the study group was significantly lower than that in the control group(P<0.05).There was no significant difference in the recurrence and metastasis rate between the study group and the control group(7.14%vs.4.76%,χ2=0.213,P=0.645>0.05).Conclusion Shenqifuzheng Injection can regulate the immune function of patients with NSCLC after operation and reduce the adverse reactions induced by chemotherapy.

关 键 词：参芪扶正注射液 TP化疗方案 非小细胞肺癌 免疫功能 肿瘤标志物 

分 类 号：R969.4[医药卫生—药理学] R2-031[医药卫生—药学]